Tag: Allergan
AbbVie Gets Reprieve In $63B Allergan Merger Antitrust Case
A federal judge in New York tentatively scrapped two antitrust cases: one concerning direct purchasers like CVS and Walgreens and another with end payers...
Allergan With Settle With Restasis Payers For $30M
AbbVie subsidiary Allergan will pay about US$30 million to resolve the remainder of a consolidated antitrust class action over its alleged scheme to delay...
Allergan, Merz Must Face Namenda “Pay to Delay” Antitrust Suit
A police officers’ benefit fund may represent a class of insurers and other indirect pharmaceutical purchasers on allegations that Allergan‘s Forest Laboratories unit and...
Allergan, Loestrin Buyers Get OK For $168M Birth Control Settlement
Allergan subsidiary Warner Chilcott and three groups of birth control purchasers convinced a federal judge in Rhode Island to approve settlements worth US$167.5 million...
Allergan’s $750M Alzheimer Drug Antitrust Settlement Approved
US District Judge Colleen McMahon gave final approval to resolution of antitrust litigation over the Alzheimer’s drug after a very brief fairness hearing in...
Allergan Must Face Class Action In Restasis Generic Delay Suit
Insurers, pension funds, and Restasis users accusing Allergan of conspiring to delay generic competition for the dry eye drug convinced a Brooklyn federal judge...
AbbVie Gets Final EU Approval for Allergan Buy
As part of US biopharma major AbbVie’s $6.3 billion acquisition of Ireland-incorporated Allergan announced…
To continue reading The Pharma Letter please login, subscribe or claim a 7 day free trial...
Allergan Pays To Resolve Restasis Antitrust Claims
Allergan has agreed to pay nearly US$51.3 million to resolve allegations that the drugmaker violated antitrust laws by improperly trying to delay US regulatory...
US: Allergan units resolve antitrust litigation on Loestrin
Ireland-incorporated Allergan announced on Monday, January 6, that its Warner Chilcott and Watson subsidiaries have reached resolutions with all plaintiffs, including a class of...
US: Allergan pays $750M to settle Namenda antitrust charges
Allergan will pay US$750 million to direct and indirect purchasers of its Alzheimer's disease medication Namenda, resolving a class action suit that alleged the...
